ライフサイエンスコーパス: upper respiratory tract

1 by suppressing inflammatory processes of the upper respiratory tract.

2 preceded by an unidentified infection of the upper respiratory tract.

3 f active virus replication in tissues of the upper respiratory tract.

4 nosis when SARS-CoV-2 is undetectable in the upper respiratory tract.

5 on from homologous wt virus challenge in the upper respiratory tract.

6 -negative human pathogen that resides in the upper respiratory tract.

7 the ca vaccine viruses was restricted to the upper respiratory tract.

8 nsal bacterium that frequently colonises the upper respiratory tract.

9 s pneumoniae begins with colonization of the upper respiratory tract.

10 h is associated with virus attachment to the upper respiratory tract.

11 ceded by excess bacterial density within the upper respiratory tract.

12 logous H1N1 virus challenge infection in the upper respiratory tract.

13 ve binding to human receptors present in the upper respiratory tract.

14 rrelate with the degree of protection in the upper respiratory tract.

15 and -3 were produced and secreted along the upper respiratory tract.

16 e colonizes the mucosal surface of the human upper respiratory tract.

17 OVID-19 can present as a mild illness of the upper respiratory tract.

18 cantly reduced in colonization of the murine upper respiratory tract.

19 lycan similarity between the human and swine upper respiratory tract.

20 se and initiates infection by colonizing the upper respiratory tract.

21 m that initiates infection by colonizing the upper respiratory tract.

22 preceded by asymptomatic colonization of the upper respiratory tract.

23 4 samples collected, 228 (97%) were from the upper respiratory tract.

24 dies in resolution of RSV-A infection in the upper respiratory tract.

25 to the intrinsic conditions within the host upper respiratory tract.

26 luenza virus targets epithelial cells in the upper respiratory tract.

27 ival in the extracellular environment of the upper respiratory tract.

28 orrelation with the replication in the human upper respiratory tract.

29 ased viral replication in both the lower and upper respiratory tracts.

30 Tonsils are the lymph nodes serving the upper respiratory tract, acting as both induction and ef

31 ificantly reduced the SARS-CoV-2 load in the upper respiratory tract and completely suppressed spread

32 (NTHi) initiates infection by colonizing the upper respiratory tract and is a common cause of localiz

33 ae is an opportunistic pathogen of the human upper respiratory tract and is often found to cause infl

34 Review looks at the landscape ecology of the upper respiratory tract and mouth and seeks greater clar

35 hich supported virus replication only in the upper respiratory tract and not in the lower respiratory

36 of s-LAIV led to complete protection in the upper respiratory tract and partial protection in the lu

37 s in efficient clearance of virus within the upper respiratory tract and rarely produces severe disea

38 tious diseases, especially infections of the upper respiratory tract and skin.

39 ata suggest that there is persistence in the upper respiratory tract and that this is key in the esta

40 y phase of influenza infection occurs in the upper respiratory tract and the trachea, but little is k

41 Respiratory viruses initially infect the upper respiratory tract and then progress to lower respi

42 Most infections (47%) involved the upper respiratory tract and were minor.

43 umococcal species that naturally inhabit the upper respiratory tract and yielded 97% (142/146) sensit

44 inovirus (hRV) is frequently detected in the upper respiratory tract, and symptomatic infection is as

45 licate well in epithelial cells of the swine upper respiratory tract, and these viruses were shown to

46 infectious dose, grow to high titers in the upper respiratory tract, and transmit efficiently among

47 of an H5N1 influenza virus in the mammalian upper respiratory tract, and yet it was insufficient to

48 AV primarily infects epithelial cells of the upper respiratory tract, APCs are also susceptible.

49 ower gastrointestinal tract, rather than the upper respiratory tract, as the likely source community

50 tissue infections, this is beneficial in the upper respiratory tract because it disrupts colonization

51 all viruses replicated to high titers in the upper respiratory tract but produced only mild illness.

52 s, all of the viruses replicated well in the upper respiratory tract, but the equine viruses replicat

53 pneumococcus may promote colonization of the upper respiratory tract by enhancing the ability of the

54 mptomatic and persistent colonization of the upper respiratory tract by Neisseria meningitidis occurs

55 sampled by bronchoalveolar lavage (BAL) and upper respiratory tract by oropharyngeal wash (OW).

56 Molecular detection of RVs from the upper respiratory tract can be prolonged, complicating e

57 Whereas upper respiratory tract carriage precedes disease for bo

58 within the lungs; however, their effects on upper respiratory tract carriage remain unknown.

59 The ability to detect SARS-CoV-2 in the upper respiratory tract ceases after 2 to 3 weeks post-s

60 ceptibility to early allergic sensitization, upper respiratory tract colonization with bacterial path

61 association between colonization density of upper respiratory tract colonizers and pathogen-specific

62 as less frequently observed in patients with upper respiratory tract disease only and more frequently

63 s by county were estimated for uncomplicated upper respiratory tract encounters (acute otitis media,

64 Of 246866 uncomplicated upper respiratory tract encounters, antibiotics were dis

65 NiV initially replicated in the upper respiratory tract epithelium, whereas HeV initiate

66 ee DNA liberated from other organisms in the upper respiratory tract, facilitating immune evasion and

67 entifying the molecular changes that enhance upper respiratory tract fitness, increased resistance to

68 firmation of active virus replication in the upper respiratory tract has implications for the contain

69 pathogen that is commonly found in the human upper respiratory tract, has only four identified two-co

70 ines) and treat (antivirals) infection, this upper respiratory tract human pathogen remains a global

71 t commonly, visits were reportedly for acute upper respiratory tract illnesses (sore throat, 34.3%; e

72 ard-dose group, or number of parent-reported upper respiratory tract illnesses between groups (625 fo

73 ns, noninfluenza infections, parent-reported upper respiratory tract illnesses, time to first upper r

74 iruses (hCoV) usually cause mild to moderate upper-respiratory tract illnesses, except SARS-CoV and M

75 An upper respiratory tract immunization (URTI) model was de

76 he ability to bind to receptors in the human upper respiratory tract in combination with several fami

77 ted EHV-1 challenge virus replication in the upper respiratory tract in fully protected horses.

78 us) parasuis is a commensal bacterium of the upper respiratory tract in pigs and also the causative a

79 o colonize and persist in the lower, but not upper, respiratory tract in rats and mice.

80 The human upper respiratory tract, including the nasopharynx, is c

81 fluenza (13 [12%]), headache (11 [10%]), and upper respiratory tract infection (11 [10%]).

82 g vs nine [43%] patients receiving placebo), upper respiratory tract infection (11 [25%] patients vs

83 mmon adverse events in all groups were viral upper respiratory tract infection (14-16%) and worsening

84 t infection (19 [7%] vs 11 [4%] vs 13 [5%]), upper respiratory tract infection (15 [5%] vs 15 [5%] vs

85 hesia (22 [10%] and 11 [5%] vs 10 [5%]), and upper respiratory tract infection (20 [9%] and 23 [11%]

86 tmares or abnormal dreams (4 [10%] vs none), upper respiratory tract infection (3 [7%] vs none], and

87 nasopharyngitis (30 [11%] vs 15 [11%]), and upper respiratory tract infection (35 [12%] vs ten [7%])

88 The most common adverse events were upper respiratory tract infection (36 [10%] patients) an

89 n adverse events included fatigue (62%), and upper respiratory tract infection (42%), infusion reacti

90 op 3 prevalent ARI syndromes included: viral upper respiratory tract infection (47%), pharyngitis (18

91 8.0%), sinusitis (4.0% and 6.3%), and viral upper respiratory tract infection (5.8% and 4.4%) for bu

92 [14%]), headache (57 [15%] vs 46 [12%]), and upper respiratory tract infection (51 [13%] vs 30 [8%]).

93 The most common adverse events overall were upper respiratory tract infection (51 [9%] of 581 patien

94 7%] patients), rhinitis (10 [16%] patients), upper respiratory tract infection (7 [11%] patients), an

95 patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia

96 e events were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (

97 brodalumab groups were nasopharyngitis (8%), upper respiratory tract infection (8%), and injection-si

98 ents [5.2%]; placebo, 89 events [5.0%]), and upper respiratory tract infection (aclidinium, 86 events

99 ear 10, 2.75; 95% CI, 2.03 to 3.73), current upper respiratory tract infection (adjusted odds ratio,

100 te otitis media development, but symptomatic upper respiratory tract infection (as opposed to asympto

101 s were pyrexia (eight [73%] of 11 patients), upper respiratory tract infection (eight [73%]), cranios

102 uded mild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 4

103 The most frequent adverse events were upper respiratory tract infection (placebo 6 [7%] patien

104 significantly worse survival than those with upper respiratory tract infection (probable: hazard rati

105 erse events in both groups were headache and upper respiratory tract infection (ten [16%] for both ev

106 d with an increased risk of progression from upper respiratory tract infection (URI) to LRD.

107 surement properties in acute cough caused by upper respiratory tract infection (URTI) and longitudina

108 interval (months 1-6 and month 9) and during upper respiratory tract infection (URTI) episodes.

109 the association between vitamin D status and upper respiratory tract infection (URTI) have given mixe

110 y controls, whether to exclude controls with upper respiratory tract infection (URTI) or nonsevere pn

111 DYC was completed daily from the onset of an upper respiratory tract infection (URTI) until asthma sy

112 ts were grouped according to the presence of upper respiratory tract infection (URTI) without lower r

113 s about paediatric diarrhoea and adult acute upper respiratory tract infection (URTI), which were pre

114 life (QoL) assessments and the incidence of upper respiratory tract infection (URTI).

115 There are no antivirals to treat viral upper respiratory tract infection (URTI).

116 n used for respiratory syncytial virus (RSV) upper respiratory tract infection and lower respiratory

117 commonly reported adverse events (AEs) were upper respiratory tract infection and stomatitis of most

118 At presentation, most patients (70%) had an upper respiratory tract infection and the remaining pati

119 A week before the onset of symptoms, a mild upper respiratory tract infection had developed.

120 9 [50%] women), clinical presentation was an upper respiratory tract infection in 12 (67%), and viral

121 ea in the pitavastatin group (n=12, 10%) and upper respiratory tract infection in the pravastatin gro

122 RSV usually presents as an upper respiratory tract infection in this patient popula

123 ast day their child exhibited symptoms of an upper respiratory tract infection or asthma exacerbation

124 ily a childhood disease that occurs after an upper respiratory tract infection or impetigo; its occur

125 st benefit of ribavirin-based therapy at the upper respiratory tract infection stage and the highest

126 es a spectrum of diseases, ranging from mild upper respiratory tract infection to severe lower respir

127 Upper respiratory tract infection was the most frequent

128 itis media (AOM) is a common complication of upper respiratory tract infection whose pathogenesis inv

129 all expansion of CD8(+) T cells following an upper respiratory tract infection with a pathogenic infl

130 common adverse events were nausea, anaemia, upper respiratory tract infection, and headache.

131 on of which were nasopharyngitis, influenza, upper respiratory tract infection, and headache.

132 ents in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 pati

133 ommonly reported adverse events were asthma, upper respiratory tract infection, and headache; 9 patie

134 ced among groups, were most commonly asthma, upper respiratory tract infection, and injection site re

135 ent adverse events were injection-site pain, upper respiratory tract infection, and nausea.

136 r respiratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyv

137 mab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF;

138 The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea.

139 dache, peripheral edema, skin ulcer, anemia, upper respiratory tract infection, diarrhea, and nasopha

140 The most common AEs included arthralgia, upper respiratory tract infection, headache, fatigue, an

141 zation of the respiratory tract during viral upper respiratory tract infection, in addition to the re

142 common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back p

143 with DARA-MD 1200 mg were thrombocytopenia, upper respiratory tract infection, insomnia, and decreas

144 grade 3 infections (two lung infections, one upper respiratory tract infection, one sepsis, and one m

145 Anemia (33.3%), upper respiratory tract infection, pyrexia, and diarrhea

146 In this population of young children with upper respiratory tract infection, RV/EV accounted for t

147 iously healthy individuals with a history of upper respiratory tract infection, soft tissue contusion

148 Such common diagnoses as upper respiratory tract infection, urinary tract infecti

149 cription following a primary diagnosis of an upper respiratory tract infection.

150 itis media occurs as a complication of viral upper respiratory tract infection.

151 ents were pulmonary exacerbation, cough, and upper respiratory tract infection.

152 well as reduction in the incidence of viral upper respiratory tract infection.

153 of epithelial signaling in the prevention of upper respiratory tract infection.

154 Common adverse events were headache and upper respiratory tract infection.

155 were headache, cough, nasal congestion, and upper respiratory tract infection.

156 the risk of acute otitis media complicating upper respiratory tract infection.

157 growth in human saliva, an ex vivo model of upper respiratory tract infection.

158 mmon adverse events were nasopharyngitis and upper respiratory tract infection.

159 most common adverse events were headache and upper respiratory tract infection.

160 nd included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could

161 ea (n=29, 18%, and n=16, 10%, respectively); upper-respiratory-tract infection (n=17, 10%) and periph

162 both (21 [20%] of 107 vs seven [6%] of 110), upper respiratory tract infections (18 [17%] vs ten [9%]

163 bo and 67 [29%] for reslizumab for study 2), upper respiratory tract infections (32 [13%] and 39 [16%

164 ts with dupilumab compared with placebo were upper respiratory tract infections (33-41% vs 35%) and i

165 ne) were infusion reactions (56 [38%] vs 0), upper respiratory tract infections (43 [28%] vs 26 [17%]

166 nce rate ratio, 0.85; 95% CI, 0.79 to 0.91), upper respiratory tract infections (4893 vs. 5763 episod

167 appropriate antibiotic prescribing for acute upper respiratory tract infections (AURIs) requires a be

168 itis (eight [8%] patients in each group) and upper respiratory tract infections (five [5%] patients i

169 week 16, the most common adverse events were upper respiratory tract infections (four [4%], eight [8%

170 Common grade 1-2 toxicities included upper respiratory tract infections (in 28 [57%] of 49 pa

171 mporally associated with a recent history of upper respiratory tract infections (P = 0.0064), and mar

172 h a significant increase in the frequency of upper respiratory tract infections (r = -0.42, P < .001)

173 Information on upper respiratory tract infections (URTIs) and lower res

174 Upper respiratory tract infections (URTIs) are important

175 ics in Chinese primary care to children with upper respiratory tract infections (URTIs), we developed

176 xyvitamin D (25-OHD) levels and incidence of upper respiratory tract infections (URTIs).

177 rovirus, are responsible for the majority of upper respiratory tract infections and are associated wi

178 d in dietary supplements, primarily to treat upper respiratory tract infections and to support immune

179 ntimicrobial prescribing practices for viral upper respiratory tract infections are being employed by

180 was the number of laboratory-confirmed viral upper respiratory tract infections based on parent-colle

181 Viral upper respiratory tract infections have been implicated

182 luster-level proportion of prescriptions for upper respiratory tract infections in 2-14-year-old outp

183 mation is available on the viral etiology of upper respiratory tract infections in Cameroon.

184 lus influenzae frequently causes noninvasive upper respiratory tract infections in children but can a

185 luenzae (NTHi) frequently causes noninvasive upper respiratory tract infections in children but can c

186 patients.IMPORTANCE Influenza viruses cause upper respiratory tract infections in humans.

187 diagnosis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of par

188 entation reduces the incidence of wintertime upper respiratory tract infections in young children.

189 The mean number of laboratory-confirmed upper respiratory tract infections per child was 1.05 (9

190 than either Victoria lineage and (ii) fewer upper respiratory tract infections were caused by the Vi

191 42 [15%] had bronchitis, 34 [12%] had viral upper respiratory tract infections), cough (34 [12%]), a

192 ibiotic-inappropriate diagnoses (nonspecific upper respiratory tract infections, acute bronchitis, an

193 Infusion-related reactions, upper respiratory tract infections, and oral herpes infe

194 mental tobacco smoke, controller medication, upper respiratory tract infections, and seasonality.

195 respiratory pathogens, and the occurrence of upper respiratory tract infections, including otitis med

196 spitalized adults varies widely and includes upper respiratory tract infections, severe lower respira

197 yvitamin D levels and a higher risk of viral upper respiratory tract infections.

198 rilonacept were injection-site reactions and upper respiratory tract infections.

199 n of T2Rs may have therapeutic potential for upper respiratory tract infections.

200 fects humans, causing significant numbers of upper respiratory tract infections.

201 risk factor for the development of recurrent upper respiratory tract infections.

202 Numerous viruses can cause upper respiratory tract infections.

203 ced prescribing of antibiotics for childhood upper respiratory tract infections.

204 worldwide and represent the leading cause of upper respiratory tract infections.

205 tion in children for the prevention of viral upper respiratory tract infections.

206 ementation did not reduce overall wintertime upper respiratory tract infections.

207 ory infections (54 [19%] of 278 patients had upper respiratory tract infections; 42 [15%] had bronchi

208 piratory-tract infections (3742 [55.3%]) and upper-respiratory-tract infections (1416 [20.9%]), of wh

209 during seasonal changes, from patients with upper respiratory tract infectious disease, lower respir

210 ic obstructive pulmonary disease (COPD), and upper respiratory tract inflammation (URTI).

211 Upper respiratory tract inflammatory diseases such as as

212 ) infection induces clinical symptoms in the upper respiratory tract, inhibits immune responses, and

213 ) infection induces clinical symptoms in the upper respiratory tract, inhibits immune responses, and

214 Colonization of the upper respiratory tract is an initial step that may lead

215 The upper respiratory tract is continually assaulted with ha

216 The upper respiratory tract is the primary site for GAS colo

217 coccus pneumoniae, a normal commensal of the upper respiratory tract, is a major public health concer

218 asive disease notifications, emm1 S pyogenes upper respiratory tract isolates increased significantly

219 lated with reduced numbers of macrophages in upper respiratory tract lavages as well as impaired upre

220 coronavirus for viral load in the lower and upper respiratory tracts (LRT and URT, respectively), bl

221 , we examined the impact of influenza on the upper respiratory tract microbiome in a human challenge

222 species in the oropharynx, variation in the upper respiratory tract microbiome may create conditions

223 standing the composition and dynamics of the upper respiratory tract microbiota in healthy infants is

224 We sought to describe the dynamics of the upper respiratory tract microbiota in healthy infants wi

225 een N. meningitidis and other members of the upper respiratory tract microbiota, through a metabolic

226 ve infection and their fitness in an ex vivo upper respiratory tract model.

227 commensal bacteria that colonizes the human upper respiratory tract mucosa during early childhood.

228 Viral replication was observed mainly in the upper respiratory tract (nasal turbinates) but also in t

229 the bacterial communities at 2 sites of the upper respiratory tract obtained from children from a ru

230 in chickens and is limited in tropism to the upper respiratory tract of 1-day-old and 2-week-old chic

231 g and microbial community composition in the upper respiratory tract of 6-week-old infants.

232 (SARS-CoV-2) shedding was observed from the upper respiratory tract of a female immunocompromised in

233 hat the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may inc

234 d in more-efficient viral replication in the upper respiratory tract of ferrets and an increased seru

235 n did the virus replicate efficiently in the upper respiratory tract of ferrets and became more immun

236 /107/03, which replicated efficiently in the upper respiratory tract of ferrets and was capable of tr

237 emonstrating that they are expelled from the upper respiratory tract of ferrets rather than from trac

238 6-SA receptors replicated efficiently in the upper respiratory tract of ferrets, induced high levels

239 found in airways extending toward and in the upper respiratory tract of ferrets.

240 which we demonstrate commonly occurs in the upper respiratory tract of guinea pigs.

241 ed eight distinct microbiota profiles in the upper respiratory tract of healthy infants.

242 utilizing S. pneumoniae colonization of the upper respiratory tract of infant mice.

243 ated containment of viral replication in the upper respiratory tract of influenza virus-infected anim

244 replicate efficiently in the low temperature upper respiratory tract of mammals, suggesting the prese

245 Here, we show that coinfection of the upper respiratory tract of mice with influenza virus and

246 ne and equine viruses replicated well in the upper respiratory tract of mice.

247 identify the prevalence of 13 viruses in the upper respiratory tract of patients with CAP and concurr

248 jor role in facilitating colonization of the upper respiratory tract of rhesus macaques, in some case

249 nd to not be required for persistence in the upper respiratory tract of swine.

250 hat influenza B viruses can replicate in the upper respiratory tract of the guinea pig and that virus

251 ds on the surface of epithelial cells of the upper respiratory tract of the host using its own protei

252 predominantly produces IFN-gamma within the upper respiratory tract of the infected mice.

253 esting a limited effect on SARS-CoV-2 in the upper respiratory tract of this individual.

254 irus also demonstrated reduced titers in the upper respiratory tracts of ferrets; however, contact an

255 verse bacterial species that is found in the upper respiratory tracts of pigs and can also cause Glas

256 OM caused by other pathogens carried in the upper-respiratory tract of children.

257 sts that the tissue tropisms (i.e., in swine upper respiratory tracts) of avian IAVs affect their spi

258 tle is known about T cell trafficking to the upper respiratory tract or the relationship between effe

259 The lymphoid tissue that drains the upper respiratory tract represents an important inductio

260 R ligands from the gastrointestinal, but not upper respiratory, tract rescued host defenses in the lu

261 r probable LRTI, respectively) or a positive upper respiratory tract sample with radiographic abnorma

262 her MERS-CoV loads and genome fractions than upper respiratory tract samples.

263 n obtaining samples without contamination by upper respiratory tract secretions.

264 and that the virus is highly tropic for the upper respiratory tract, so testing of bird species shou

265 d efficient extraction of nucleic acids from upper respiratory tract specimens (nasal washes and swab

266 The most common virus detected in upper respiratory tract specimens was EV-D68 (from 20%,

267 r specificity (eg, detection of pathogens in upper respiratory tract specimens, which may indicate as

268 y syndrome coronavirus 2 (SARS-CoV-2) RNA in upper respiratory tract specimens.

269 l glands and surface epithelial cells of the upper respiratory tract, SPLUNC1 is thought to possess a

270 nificantly decreased ability to colonize the upper respiratory tract, suggesting that cleavage of cor

271 ulum pigrum is a commensal inhabitant of the upper respiratory tract suspected to be responsible for

272 Additionally, an augmentation of upper respiratory tract symptom scores and LRTS scores o

273 Mild upper respiratory tract symptoms and/or fever occurred i

274 ssociated with each other and with lower and upper respiratory tract symptoms when assessed longitudi

275 of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the pot

276 ed from 81 children under 1 year of age with upper respiratory tract symptoms.

277 response to RV16 at day 3 is associated with upper respiratory tract symptoms.

278 moniae forms organized biofilms in the human upper respiratory tract that may play an essential role

279 sults indicate that virus replication in the upper respiratory tract, the nasal respiratory epitheliu

280 pithelial (NHBE) cells, a model of the human upper respiratory tract, to examine the replicative capa

281 viruses replicated to similar titers in the upper respiratory tract (URT) and caused comparable dise

282 The upper respiratory tract (URT) hosts a complex microbial

283 The effects of influenza infection on the upper respiratory tract (URT) microbiome are largely unk

284 c inference of identifying a pathogen in the upper respiratory tract (URT) of children with pneumonia

285 f PVRL4 was widespread in both the lower and upper respiratory tract (URT) of macaques, indicating MV

286 Most infants suffer mild upper respiratory tract (URT) symptoms, whereas approxim

287 fected with respiratory viruses (RVs) in the upper respiratory tract (URT), but the concordance betwe

288 milar to that of a mild low-dose, low-volume upper respiratory tract (URT)-biased infection.

289 sible caused limited tissue pathology in the upper respiratory tract (URT).

290 ticle aerosols of Y. pestis in the lower and upper respiratory tracts (URTs) of mice are different.

291 wever, in the context of prior or concurrent upper respiratory tract viral infection, this bacterium

292 T-PCR cycle thresholds, suggestive of higher upper respiratory tract viral loads, but not with increa

293 Virus shedding from the upper respiratory tract was not reduced by remdesivir tr

294 lower respiratory tract, rather than in the upper respiratory tract, where resident microflora and i

295 resulted in robust virus replication in the upper respiratory tract, whereas mice deficient for MHC-

296 ad domain in reduction of viral loads in the upper respiratory tract, which could significantly reduc

297 is) is the granulomatous inflammation of the upper respiratory tract, which leads to the subsequent d

298 icient replication of the pH1N1 virus in the upper respiratory tract, which resulted in efficient hum

299 TD into 3 groups: possible (PIV detection in upper respiratory tract with new pulmonary infiltrates w

300 lus influenzae typically colonizes the human upper respiratory tract without causing disease, and yet